GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseBio Pharmaceuticals Inc (OTCPK:PHASQ) » Definitions » Dividend Payout Ratio

PHASQ (PhaseBio Pharmaceuticals) Dividend Payout Ratio : 0.00 (As of Jun. 2022)


View and export this data going back to 2018. Start your Free Trial

What is PhaseBio Pharmaceuticals Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. PhaseBio Pharmaceuticals's Dividend Payout Ratio for the months ended in Jun. 2022 was 0.00.

The historical rank and industry rank for PhaseBio Pharmaceuticals's Dividend Payout Ratio or its related term are showing as below:


PHASQ's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.47
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2025-07-07), the Dividend Yield % of PhaseBio Pharmaceuticals is 0.00%.

PhaseBio Pharmaceuticals's Dividends per Share for the months ended in Jun. 2022 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


PhaseBio Pharmaceuticals Dividend Payout Ratio Historical Data

The historical data trend for PhaseBio Pharmaceuticals's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhaseBio Pharmaceuticals Dividend Payout Ratio Chart

PhaseBio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Dividend Payout Ratio
Get a 7-Day Free Trial - - - - -

PhaseBio Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Apr24
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PhaseBio Pharmaceuticals's Dividend Payout Ratio

For the Biotechnology subindustry, PhaseBio Pharmaceuticals's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhaseBio Pharmaceuticals's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhaseBio Pharmaceuticals's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where PhaseBio Pharmaceuticals's Dividend Payout Ratio falls into.


;
;

PhaseBio Pharmaceuticals Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

PhaseBio Pharmaceuticals's Dividend Payout Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2021 )/ EPS without NRI (A: Dec. 2021 )
=0/ -2.628
=N/A

PhaseBio Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Jun. 2022 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Jun. 2022 )/ EPS without NRI (Q: Jun. 2022 )
=0/ -0.518
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PhaseBio Pharmaceuticals (OTCPK:PHASQ) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


PhaseBio Pharmaceuticals Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of PhaseBio Pharmaceuticals's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PhaseBio Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
1 Great Valley Parkway, Suite 30, Malvern, PA, USA, 19355
PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.
Executives
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Glen Burkhardt officer: VP, Human Resources C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY.,SUITE 30, MALVERN PA 19355
Jonathan Birchall officer: Chief Commercial Officer C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30, MALVERN PA 19355
William D. Humphries director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Clay Thorp director C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Edmund Harrigan director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Van Den Broek Richard director 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Peter Justin Klein director 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
David James Ballance officer: VP, Research and Sci. Affairs C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Michael York officer: VP, Corporate Development C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
John Sang Lee officer: Chief Medical Officer C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Susan Elizabeth Arnold officer: VP, Preclinical and Chem C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY DRIVE, SUITE 30, MALVERN PA 19355
Kristopher Hanson officer: VP, Head of Legal C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355

PhaseBio Pharmaceuticals Headlines

From GuruFocus

PhaseBio Pharmaceuticals to Participate in Upcoming Investor Conferences

By Business Wire Business Wire 02-27-2021

PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update

By Business Wire Business Wire 03-08-2022